^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lymphoplasmacytic Lymphoma

    Related cancers:
    3d
    Application of ⁶⁸Ga-NOTA-BCMA Nanobody PET/CT Imaging in Non-Myeloma Hematologic Malignancies (ChiCTR2500115865)
    P=N/A, N=0, Not yet recruiting, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Peking Union Medical College Hospital
    New trial
    3d
    Zanubrutinib Combined with Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in Treatment-Naive Waldenström's Macroglobulinemia: A Phase II Clinical Study (ChiCTR2500113199)
    P2, N=43, Not yet recruiting, Institute of Hematology, Chinese Academy of Medical Sciences (Chinese Academy of Medical Sciences Hematology Hospital); Institute of Hematology, Chine
    New P2 trial
    |
    Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • bendamustine
    5d
    Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (clinicaltrials.gov)
    P=N/A, N=153, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Valcyte (valganciclovir)
    5d
    BGB-3111-215t: Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment (clinicaltrials.gov)
    P2, N=96, Completed, BeiGene | Active, not recruiting --> Completed
    Trial completion
    |
    Imbruvica (ibrutinib) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib)
    6d
    BTK Inhibition in Hematology: From CLL/SLL to Emerging Applications Across B-Cell and Immune Disorders. (PubMed, Biomolecules)
    Covalent BTK inhibitors (ibrutinib, acalabrutinib, and zanubrutinib) irreversibly bind the C481 residue and have produced high response rates and durable disease control, often replacing chemoimmunotherapy in the relapsed setting and, for some entities, even in the first line. Non-covalent BTK inhibitors (e.g., pirtobrutinib) bind BTK independently of C481, can overcome classic C481-mediated resistance, and extend BTK pathway targeting into later lines of therapy. Overall, BTK inhibition has evolved into a versatile platform enabling long-term, often chemo-free management strategies.
    Review • Journal • IO biomarker
    |
    PLCG2 (Phospholipase C Gamma 2)
    |
    Imbruvica (ibrutinib) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • Jaypirca (pirtobrutinib)
    6d
    BRUIN: A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL (clinicaltrials.gov)
    P1/2, N=803, Completed, Loxo Oncology, Inc. | Active, not recruiting --> Completed | Trial completion date: Sep 2027 --> Dec 2025
    Trial completion • Trial completion date
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Jaypirca (pirtobrutinib)
    23d
    Characteristics and Outcomes of Finnish Patients with Waldenström Macroglobulinemia-A Real-World Study. (PubMed, Clin Lymphoma Myeloma Leuk)
    To our knowledge, this is the first RWE study of WM patients in Finland.
    Journal • Real-world evidence
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4)
    27d
    POD24 is a Novel Determinant of Prognosis in Patients with Waldenström Macroglobulinemia. (PubMed, Blood Adv)
    This international study evaluated 253 patients receiving frontline fixed-duration bendamustine-rituximab (BR), a common chemoimmunotherapy for WM. In conclusion, BR is effective, irrespective of the MYD88 status, but CXCR4 mutations and POD24 portend worse outcomes. Non-POD24 patients represent a cohort with distinctly favorable outcome.
    Journal • IO biomarker
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    Rituxan (rituximab) • bendamustine
    28d
    A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas (clinicaltrials.gov)
    P1/2, N=53, Active, not recruiting, Fred Hutchinson Cancer Center | Trial completion date: Nov 2037 --> Mar 2039
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    cyclophosphamide • fludarabine IV • MB-106
    28d
    FIL_BRUCE: Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval. (clinicaltrials.gov)
    P=N/A, N=212, Active, not recruiting, Fondazione Italiana Linfomi - ETS | Recruiting --> Active, not recruiting | N=125 --> 212
    Enrollment closed • Enrollment change
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    Brukinsa (zanubrutinib)
    30d
    IgG-type lymphoplasmacytic lymphoma with light chain deposition disease. (PubMed, CEN Case Rep)
    As non-IgM LPL cases have historically been associated with poorer prognoses compared to Waldenström macroglobulinemia, the identification of underlying kidney complications such as LCDD is essential. Further accumulation of similar cases is needed to establish optimal treatment strategies.
    Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
    1m
    NCI-2018-01880: Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=27, Active, not recruiting, City of Hope Medical Center | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • Aliqopa (copanlisib)